Becton Dickinson highlights recall and new contract, shares in S&P 500 medtech focus

Becton Dickinson faces a voluntary recall of select skin preparation products while securing an innovative technology contract with Vizient, keeping the S&P 500 medtech name in focus for investors tracking regulatory risk and hospital demand.

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-29, 10:13.

Becton Dickinson (US0718131099) combines regulatory scrutiny with commercial progress this week. The S&P 500-listed medtech group has issued a voluntary recall for select skin preparation products and reported a new innovative technology contract with hospital alliance Vizient according to recent releases and market coverage.

What recent releases show

According to a company update, Becton Dickinson has initiated a voluntary recall for certain BD skin preparation products after identifying quality concerns, with details carried in a late June communication and picked up by sector news outlets. Finanzen100 aggregates recent headlines on BD regulatory actions

At the same time, the group reported that BD has been awarded a Vizient Innovative Technology contract for its CentroVena One insertion system, which is designed to support vascular access procedures in hospitals, as highlighted in a June 23 note. A BD press release via PR Newswire details the Vizient contract

Analyst views and recent performance

Market commentary this week notes that BDX shares have recently ticked higher, with one data provider citing a roughly 3 percent move and still describing the stock as undervalued based on a GF Score of 76 out of 100 for fundamentals and valuation. GuruFocus reports on BDX recent share move and GF Score

In parallel, Bank of America has trimmed its price target for Becton Dickinson, citing wider medtech headwinds and a more cautious view on margin progression, according to summaries of recent analyst actions. A GuruFocus analyst round-up references the latest BofA target change

The product behind the stock

Becton Dickinson generates a substantial share of its revenue from medical devices such as infusion systems and vascular access products, including the CentroVena One insertion system cited in the recent Vizient contract. The company also sells diagnostic instruments and laboratory consumables to hospitals and research institutions worldwide.

Where the stock trades today

The Becton Dickinson shares (US0718131099) last closed on the NYSE at 156.06 US dollars as of 2026-06-26, 15:59 Eastern, according to recent quote data.

Key data on the Becton Dickinson shares

• Company: Becton, Dickinson and Company
• ISIN: US0718131099
• WKN: 857675
• Ticker: BDX
• Trading venue: NYSE
• Price (as of 2026-06-26, 15:59): 156.06 USD
• Market cap: 45.0 billion USD (as of 2026-06-26)
• Sector / industry: Health Care Equipment & Supplies
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This text is for informational purposes only and does not contain investment advice, investment recommendations or financial analysis. It does not replace individual, professional investment or other advice.